Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
08 Dezember 2021 - 10:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2021
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad Oncology SA
On December 8, 2021, Celyad Oncology SA (the Company) issued a press release to announce the closing of its $32,500,000 private
placement with an affiliate of Fortress Investment Group, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1 is hereby incorporated by
reference into the Companys Registration Statements on Form F-3 (File No. 333-248464) and Form S-8 (File No. 333-220737).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA
|
|
|
|
Date: December 8, 2021
|
|
By:
|
|
/s/ Filippo Petti
|
|
|
|
|
Filippo Petti
Chief Executive Officer and
Financial Officer
|
Celyad (CE) (USOTC:CLYYF)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Celyad (CE) (USOTC:CLYYF)
Historical Stock Chart
Von Okt 2023 bis Okt 2024
Echtzeit-Nachrichten über Celyad SA (CE) (OTCMarkets): 0 Nachrichtenartikel
Weitere Celyad Oncology Sa News-Artikel